Thomas Nusbickel - 18 Feb 2022 Form 4 Insider Report for CorMedix Inc. (CRMD)

Reporting relationship: EVP, Chief Commercial Officer
Issuer ticker: CRMD
Reported as of: 18 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Feb 2022, 15:14:08 UTC
Prior SEC filing: 20 May 2021
Source filing: View source filing
Reporting owner signature: /s/ Thomas Nusbickel

Key filing fact

Thomas Nusbickel filed Form 4 for CorMedix Inc. (CRMD) on 23 Feb 2022.

Key facts

This page summarizes Thomas Nusbickel's Form 4 filing for CorMedix Inc. (CRMD).
1 reported transaction and 3 derivative rows are listed below.
Accepted by SEC: 23 Feb 2022, 15:14.

Change

Previous filing in this sequence was filed on 20 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRMD transaction Derivative

Stock Option (Right to Buy Common Stock)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 18 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 100,000
Exercise price: $4.03
Footnotes: F1

CRMD holding Derivative

Stock Option (Right to Buy Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 260,000
Date: 18 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 260,000
Exercise price: $7.56
Footnotes: F2

CRMD holding Derivative

Stock Option (Right to Buy Common Stock)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 7,500
Date: 18 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,500
Exercise price: $7.56
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

These options were granted on 02/18/2022. These options vest 1/4 on the date of grant, 1/4 on the first anniversary of the date of grant, 1/4 on the second anniversary of the date of grant and 1/4 on the third anniversary of the date of grant.

Footnote F2

The options vest as follows: 160,000 will vest over four years in four (4) equal installments on the first four anniversaries of May 13, 2021. The remaining 100,000 options vest on the achievement of certain milestones, subject to continued employment.

Footnote F3

These options were granted on May 13, 2021. These options shall vest in full on the first anniversary of the grant date, subject to continued employment.